Skip to main content
. 2022 Aug 1;61(3):112. doi: 10.3892/ijo.2022.5402

Figure 5.

Figure 5

Knocking down HHLA2 expression inhibits the proliferation, migration and invasion of GBC cells in vitro and tumour formation in vivo. (A) According to the wound-healing assay, which was (B) quantified, HHLA2 knockdown suppressed cell migration. Scale bars, 100 µm. (C) HHLA2 knockdown decreased cell invasion, (D) according to subsequent quantification. Scale bars, 100 µm. (E) Cell proliferation ability in HHLA2 knockdown group was evaluated using EdU assay, which was (F) quantified. Scale bars, 100 µm. Green: EdU; Blue: DAPI. (G) Representative images of mice harboring GBC tumors. HHLA2 knockdown reduced the tumorigenic ability of GBC cells according to the mouse xenograft assay both (H) in terms of size and (I) weight (n=6). **P<0.01 and ***P<0.001 (shHHLA2 group vs. sh-NC group). HHLA2, human endogenous retrovirus-H long terminal repeat-associating protein 2; GBC, gall bladder cancer; shRNA or sh, short hairpin RNA; NC, negative control.